OncoMatch/Clinical Trials/NCT06855771
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Official title: A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of Navlimetostat (BMS-986504) Monotherapy and in Combination With Izalontamab Brengitecan in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss After Progression on Prior Therapies
Is NCT06855771 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including BMS-986504 and Izalontamab Brengitecan for carcinoma, non-small-cell lung.
Treatment: BMS-986504 · Izalontamab Brengitecan — The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP homozygous deletion
homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation
Required: MTAP loss
homozygous MTAP deletion or MTAP loss
Allowed: EGFR any tested
Participants with EGFR mutant or wild type NSCLC are allowed
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced or metastatic NSCLC
Documented radiographic disease progression on or after the most recent line of treatment
Cannot have received: PRMT5 inhibitor
Prior treatment with a PRMT5 ... inhibitor
Cannot have received: MAT2A inhibitor
Prior treatment with a ... MAT2A inhibitor
Cannot have received: antibody and/or ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload
Exception: except amivantamab
Prior therapy with iza-bren or any other antibody and/or ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload, except amivantamab
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0088 · Anchorage, Alaska
- Dana-Farber Cancer Institute · Boston, Massachusetts
- Karmanos Cancer Institute · Detroit, Michigan
- Washington University School of Medicine · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06855771 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PRMT5 inhibitor, MAT2A inhibitor, antibody and/or ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload disqualifies patients from enrollment.
Does this trial require MTAP?
Yes, MTAP homozygous deletion is a required biomarker for enrollment.
Does this trial require MTAP?
Yes, MTAP loss is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages